Pharmaceutical News

RSS

Preclinical study shows treatment with DAS181 inhibits infection with multiple HPIV strains

NexBio, Inc. announced today the publication of a "Major Article" in the Journal of Infectious Diseases of a preclinical study showing that treatment with DAS181 (Fludase) inhibits infection with multiple human parainfluenza virus strains. DAS181 is a broad spectrum host-targeted investigational drug candidate for treatment and prevention of Influenza-Like Illness.

19 Jun 2010

Drug-resistant malaria spreading beyond Western Cambodia, U.S. malaria coordinator says

Resistance to artemisinin-based malaria medications seems to be spreading beyond western Cambodia, where it was first detected, U.S. global malaria coordinator Timothy Ziemer said during a visit to the region this week for a conference, Agence France-Presse reports.

19 Jun 2010

USAID pledges $1.2M in support for national polio vaccination campaigns across Central Asia

The United States Agency for International Development has pledged $1.2 million in support for national poliomyelitis vaccination campaigns across Central Asia to fight the first outbreak of polio in the region since 2002.

19 Jun 2010

La Clínica de La Razaa selects Wellpartner to administer 340B Drug Discount Program

Wellpartner, a nationally recognized provider of pharmacy distribution and contract pharmacy services, today announced the addition of La Clínica de La Raza in Oakland, CA, to its rapidly expanding list of community health organization clients. Working with Wellpartner, La Clínica has chosen Safeway as its retail pharmacy partner for this program.

19 Jun 2010

SAHM strongly recommends HPV vaccines for males

On May 28, 2010, the Advisory Committee on Immunization Practices published its guidance for use of the quadrivalent HPV vaccine in males. While noting that the vaccine was approved by the FDA for use in males ages 9 through 26 to reduce their likelihood of acquiring genital warts and that it therefore could be given for this purpose, the statement released by ACIP did not recommend routine HPV vaccination of males.

19 Jun 2010

HBSS reaches $103M settlement with Astra Zeneca

Hagens Berman Sobol Shapiro (HBSS) today announced it has reached a proposed $103 million settlement with Astra Zeneca (AZ) on behalf of consumers and third party purchasers. The class-action lawsuit claimed Astra Zeneca inflated the Average Wholesale Price (AWP), which is used as a benchmark for almost all prescription drug sales in the United States.

19 Jun 2010

Lawmakers want crackdown on drug agreements that keep generics out

Democrats are looking at proposals to crack down on licensing agreements between drug companies that keep generic drugs out of the market, Politico reports. In the agreements, pharmaceutical companies pay generic manufacturers to "delay introduction of generic drugs, which are often cheaper than brand-name drugs.

18 Jun 2010

Advisory panel recommends FDA approve new "morning after" pill

The New York Times: A Food and Drug Administration advisory panel Thursday recommended that the agency approve "a medicine that could help prevent pregnancy if taken as late as five days after unprotected sex. The pill, called ella, sprang from government labs and appears to be more effective than Plan B, a morning-after pill now available over the counter to women 18 and older that gradually loses efficacy after intercourse and can be taken at latest three days after sex.

18 Jun 2010

Walgreens reaches agreement with CVS Caremark on participation in PBM national retail network

CVS Caremark Corporation and Walgreens today announced that the companies have reached an agreement on terms under which Walgreens will continue participating in the CVS Caremark pharmacy benefit management (PBM) national retail network for existing, new or renewal plans. The companies are not disclosing the financial terms of the new contract.

18 Jun 2010

Matrix Laboratories receives FDA approval for generic version Zocor Tablets: Mylan

Mylan Inc. today announced that its subsidiary Matrix Laboratories Limited has received final approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application for Simvastatin Tablets USP, 5 mg, 10 mg, 20 mg, 40 mg and 80 mg, the generic version of Merck & Co.'s Zocor Tablets, a treatment for high cholesterol. The product will be distributed by Mylan Pharmaceuticals Inc.

18 Jun 2010

Cyclacel files Answer and Counterclaims to Celgene's declaratory judgment complaint

Cyclacel Pharmaceuticals, Inc., a biopharmaceutical company developing oral therapies that target the various phases of cell cycle control for the treatment of cancer and other serious disorders, today announced that it filed its Answer and Counterclaims to the declaratory judgment complaint filed by Celgene Corporation.

18 Jun 2010

FVL gene mutation increases risk of blood clots in breast cancer patients treated with tamoxifen: Study

Women who develop blood clots while taking tamoxifen for early-stage breast cancer are more likely to carry a faulty version of a gene involved in clotting than those who do not develop blood clots, a US study has found.

18 Jun 2010

USFDA approves Sun Pharma's generic Xanax ANDA

Sun Pharma announced that USFDA has granted an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of Xanax®, alprazolam tablets.

18 Jun 2010

90% of HCV patients to be treated with triple therapy regimens, finds Decision Resources

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, based on clinical profiles provided to them, surveyed clinicians estimate that one year after the launch of Vertex Pharmaceuticals/Johnson & Johnson/Mitsubishi Tanabe Pharma's telaprevir and Merck's boceprevir, at least 90 percent of hepatitis C virus patients will be treated with triple therapy regimens.

18 Jun 2010

NAN warns health care practitioners about dangers posed by EPHINEPHrine shortage

A National Alert for Serious Medication Errors was issued yesterday by the American Society of Health-System Pharmacists and the Institute for Safe Medication Practices, warning health care practitioners about dangerous medication errors that could be caused by a shortage of EPINEPHrine pre-filled syringes.

18 Jun 2010

Data on BYETTA and SYMLIN injections, BYDUREON drug candidate to be presented at ADA 2010

Amylin Pharmaceuticals, Inc. today announced that the Company will present data for its FDA-approved diabetes drugs, BYETTA (exenatide) injection and SYMLIN (pramlintide acetate) injection, and its investigational diabetes drug candidate BYDUREON (exenatide extended-release for injectable suspension) at the American Diabetes Association's 70th Annual Scientific Sessions being held in Orlando, FL from June 25 to June 29.

18 Jun 2010

WSJ: Study on eye medicine reveals possible savings for Medicare

The Wall Street Journal reports that Medicare could save $500 million a year by switching from one type of eye medicine to another, both made by Genentech, "according to a draft study by federal officials and a University of Miami eye doctor.

18 Jun 2010

Nurse-monitored ART found to be as safe, effective as therapy monitored by doctors in South African trial

"HIV drugs can be administered as effectively by nurses as by doctors, a finding that could yield major benefits in the fight against AIDS in Africa," according to a study published online Wednesday in the Lancet, Agence France-Presse reports.

18 Jun 2010

UF administers Lumizyme for late-onset Pompe disease

The first commercially available treatment in the United States for patients with late-onset Pompe disease was administered Wednesday, June 16, at the University of Florida.

18 Jun 2010

Drug makers face tightened regulations by FDA and less clout at medical meetings

The Washington Post: "The Food and Drug Administration this week began posting online the results of safety evaluations of recently approved drugs and vaccines. The action follows a law enacted in 2007 that requires the agency to provide more safety information to consumers and health professionals. The evaluations must be conducted 18 months after a new drug comes on the market.

18 Jun 2010

Pharmaceutical News

Preclinical study shows treatment with DAS181 inhibits infection with multiple HPIV strains

Drug-resistant malaria spreading beyond Western Cambodia, U.S. malaria coordinator says

USAID pledges $1.2M in support for national polio vaccination campaigns across Central Asia

La Clínica de La Razaa selects Wellpartner to administer 340B Drug Discount Program

SAHM strongly recommends HPV vaccines for males

HBSS reaches $103M settlement with Astra Zeneca

Lawmakers want crackdown on drug agreements that keep generics out

Advisory panel recommends FDA approve new "morning after" pill

Walgreens reaches agreement with CVS Caremark on participation in PBM national retail network

Matrix Laboratories receives FDA approval for generic version Zocor Tablets: Mylan

Cyclacel files Answer and Counterclaims to Celgene's declaratory judgment complaint

FVL gene mutation increases risk of blood clots in breast cancer patients treated with tamoxifen: Study

USFDA approves Sun Pharma's generic Xanax ANDA

90% of HCV patients to be treated with triple therapy regimens, finds Decision Resources

NAN warns health care practitioners about dangers posed by EPHINEPHrine shortage

Data on BYETTA and SYMLIN injections, BYDUREON drug candidate to be presented at ADA 2010

WSJ: Study on eye medicine reveals possible savings for Medicare

Nurse-monitored ART found to be as safe, effective as therapy monitored by doctors in South African trial

UF administers Lumizyme for late-onset Pompe disease

Drug makers face tightened regulations by FDA and less clout at medical meetings

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News